Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relugolix vs Leuprolide on Cardiovascular Function in Prostate Cancer
NCT06330805Phase 2Recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Aug 2024
- Primary completion
- Dec 2027
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of tissue-plasminogen activator in prostate cancer (PCa), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started Aug 2024; status: recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06330805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06330805.